Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
Harris JE, Pandya AG, Lebwohl M, Hamzavi IH, Grimes P, Gottlieb AB, Sofen HL, Moore AY, Wang M, Kornacki D, Butler K, Rosmarin D. Harris JE, et al. Among authors: pandya ag. Skin Health Dis. 2024 Aug 7;4(6):e404. doi: 10.1002/ski2.404. eCollection 2024 Dec. Skin Health Dis. 2024. PMID: 39624731 Free PMC article. No abstract available.
Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial.
Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. Hamzavi I, et al. Among authors: pandya ag. J Am Acad Dermatol. 2022 Jun;86(6):1398-1401. doi: 10.1016/j.jaad.2021.05.047. Epub 2021 Jun 2. J Am Acad Dermatol. 2022. PMID: 34089797 Free article. Clinical Trial. No abstract available.
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Rosmarin D, et al. Among authors: pandya ag. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. N Engl J Med. 2022. PMID: 36260792
Vitiligo is not a cosmetic disease.
Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, Pandya AG; Vitiligo Working Group. Ezzedine K, et al. Among authors: pandya ag. J Am Acad Dermatol. 2015 Nov;73(5):883-5. doi: 10.1016/j.jaad.2015.07.039. J Am Acad Dermatol. 2015. PMID: 26475548 No abstract available.
Current and emerging treatments for vitiligo.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group. Rodrigues M, et al. Among authors: pandya ag. J Am Acad Dermatol. 2017 Jul;77(1):17-29. doi: 10.1016/j.jaad.2016.11.010. J Am Acad Dermatol. 2017. PMID: 28619557 Review.
Treatment recommendations for patients with vitiligo during COVID-19.
Rodrigues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, Harris JE. Rodrigues M, et al. Among authors: pandya ag. Australas J Dermatol. 2021 Aug;62(3):e481-e482. doi: 10.1111/ajd.13610. Epub 2021 May 24. Australas J Dermatol. 2021. PMID: 34028796 Free PMC article. No abstract available.
New discoveries in the pathogenesis and classification of vitiligo.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group. Rodrigues M, et al. Among authors: pandya ag. J Am Acad Dermatol. 2017 Jul;77(1):1-13. doi: 10.1016/j.jaad.2016.10.048. J Am Acad Dermatol. 2017. PMID: 28619550 Review.
174 results